Prevalence, Incidence, and Clinical Relevance of the Reverse Transcriptase V207I Mutation Outside the YMDD Motif of the Hepatitis B Virus Polymerase during Lamivudine Therapy

ABSTRACT The reverse transcriptase V207I mutation within the hepatitis B virus (HBV) polymerase is associated with resistance to lamivudine in vitro. The prevalence of this mutation in treatment-naïve patients was 1% (1/96). A follow-up of the patient carrying this mutation prior to treatment revealed no loss of sensitivity of HBV to lamivudine in vivo.

[1]  F. Pozo,et al.  Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. , 2004, Enfermedades infecciosas y microbiologia clinica.

[2]  E. Puchhammer-Stöckl,et al.  Viral features of lamivudine resistant hepatitis B genotypes A and D , 2004, Hepatology.

[3]  C-F Kao,et al.  Mechanisms for Inhibition of Hepatitis B Virus Gene Expression and Replication by Hepatitis C Virus Core Protein* , 2003, The Journal of Biological Chemistry.

[4]  S. Locarnini.  Hepatitis B viral resistance: mechanisms and diagnosis. , 2003, Journal of hepatology.

[5]  M. Sata,et al.  Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. , 2001, Journal of hepatology.

[6]  E. Sagnelli,et al.  Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis , 2000, Hepatology.

[7]  K. Loeb,et al.  High‐Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection System , 2000, Hepatology.

[8]  C. Gibbs,et al.  In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance , 2000, Hepatology.

[9]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[10]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[11]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.